![Frontiers | High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study Frontiers | High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study](https://www.frontiersin.org/files/Articles/539252/fonc-10-01470-HTML/image_m/fonc-10-01470-t004.jpg)
Frontiers | High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study
![Cancer du sein luminal et apport des classifications intrinsèques moléculaires : comment identifier les tumeurs luminales A et B en 2015 ? - ScienceDirect Cancer du sein luminal et apport des classifications intrinsèques moléculaires : comment identifier les tumeurs luminales A et B en 2015 ? - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0007455115312169-gr2.jpg)
Cancer du sein luminal et apport des classifications intrinsèques moléculaires : comment identifier les tumeurs luminales A et B en 2015 ? - ScienceDirect
![Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses | npj Breast Cancer Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses | npj Breast Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41523-019-0116-8/MediaObjects/41523_2019_116_Fig6_HTML.png)
Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses | npj Breast Cancer
![PDF) Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives A B PDF) Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives A B](https://www.researchgate.net/profile/Dimitrios-Zardavas/publication/264088331/figure/tbl2/AS:614084886138887@1523420654263/pCR-After-Neoadjuvant-Chemotherapy-in-Luminal-B-Breast-Cancer_Q320.jpg)
PDF) Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives A B
![A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer - Chinese Journal of Cancer Research A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer - Chinese Journal of Cancer Research](https://www.cjcrcn.org/data/201704PIC/cjcr-29-4-351-g00T1.jpg)
A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer - Chinese Journal of Cancer Research
![Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5582615f848e686710455b6e112e876e1ab5fb5a/6-Figure2-1.png)
Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar
![Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2F1756-0500-5-376/MediaObjects/13104_2011_Article_1552_Fig4_HTML.jpg)
Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text
![IJMS | Free Full-Text | Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer IJMS | Free Full-Text | Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer](https://www.mdpi.com/ijms/ijms-21-07661/article_deploy/html/images/ijms-21-07661-g005.png)
IJMS | Free Full-Text | Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
![Table 2 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar Table 2 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5582615f848e686710455b6e112e876e1ab5fb5a/3-Table2-1.png)
Table 2 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar
![Table 1 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar Table 1 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5582615f848e686710455b6e112e876e1ab5fb5a/2-Table1-1.png)
Table 1 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar
![Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression | Molecular Diagnosis & Therapy Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression | Molecular Diagnosis & Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40291-021-00525-7/MediaObjects/40291_2021_525_Fig1_HTML.png)
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression | Molecular Diagnosis & Therapy
![Table 2 from Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Semantic Scholar Table 2 from Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fff123e1eaa7eaf63feb07ce7031d4f0f838a8e4/7-Table2-1.png)
Table 2 from Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Semantic Scholar
![Biological Characteristics of Breast Cancer among Jordanian Women: A retrospective Single Center Cohort Study Biological Characteristics of Breast Cancer among Jordanian Women: A retrospective Single Center Cohort Study](https://www.sgo-iasgo.com/img/articles/mahmoud-al-balas-img1.jpg)
Biological Characteristics of Breast Cancer among Jordanian Women: A retrospective Single Center Cohort Study
![Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2F1756-0500-5-376/MediaObjects/13104_2011_Article_1552_Fig1_HTML.jpg)